沙利度胺治疗结缔组织病相关肺间质疾病的临床观察

Clinical observation of thalidomide in treatment of connective tissue disease associated interstitial lung disease

目的评估激素联合沙利度胺治疗结缔组织病肺间质纤维化(CTD-ILD)的有效性及安全性。方法将66例患者随机分为两组:对照组予醋酸泼尼松等常规治疗,联合组在上述基础上口服沙利度胺,疗程为6个月。结果联合组患者临床症状、肺功能、肺CT改善程度均优于对照组(P<0.05)。治疗过程中,两组患者不良反应发生情况无显著差异(P>0.05)。结论沙利度胺治疗CTD-ILD能够提高治疗效果,且无明显不良反应。

Objective To evaluate the efficacy and safety of steroid combined with thalidomide in the treatment of connective tissue disease with interstitial lung fibrosis(CTD-ILD).Methods Sixty-six patients were randomly divided into two groups:control group was given prednisone acetate and other routine treatment.The combined group took thalidomide more,and the course of treatment was six months.Results The clinical symptoms,pulmonary function and pulmonary CT improvement in combined group were better than those in control group(P<0.05).In the course of treatment,there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion Thalidomide in the treatment of CTD-ILD can improve the therapeutic effect and has no obvious adverse reactions.